Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$51.87
+1.6%
$53.66
$13.47
$72.98
$11.43B2.0837.33 million shs23.13 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$625.15
-2.5%
$774.10
$623.78
$972.53
$607.37B0.444.83 million shs14.09 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
+1.61%-17.10%+1.43%-0.33%+223.38%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.35%-17.90%-20.57%-15.09%-19.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.7 of 5 stars
2.03.00.00.02.93.31.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9993 of 5 stars
4.34.03.34.03.83.33.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
1.92
Reduce$39.83-23.21% Downside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.67
Moderate Buy$984.4157.47% Upside

Current Analyst Ratings Breakdown

Latest LLY and HIMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,050.00 ➝ $895.00
8/7/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/7/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$715.00
8/5/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
7/17/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$45.00 ➝ $48.00
7/11/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$936.00 ➝ $942.00
7/10/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$1,133.00 ➝ $1,135.00
6/24/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$45.00
6/23/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell ➝ Sell
6/23/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$30.00
6/23/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderperform ➝ Underperform
(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$1.48B7.86$0.36 per share144.96$2.51 per share20.67
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B13.15$13.89 per share45.02$15.03 per share41.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$126.04M$0.8064.8499.753.239.63%26.26%13.06%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$12.2940.8620.090.9125.91%98.25%17.92%N/A

Latest LLY and HIMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.59$6.31+$0.72$6.29$14.40 billion$15.56 billion
8/4/2025Q2 2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.18$0.17-$0.01$0.17$550.06 million$544.83 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.96%N/A48.82%11 Years

Latest LLY and HIMS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
1.72
4.98
1.32
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.18
1.37
1.06

Institutional Ownership

CompanyInstitutional Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
13.71%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
1,637223.83 million193.15 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000947.74 million946.50 millionOptionable

Recent News About These Companies

Eli Lilly: Another Not-To-Miss Dip
Decoding Eli Lilly and Co (LLY): A Strategic SWOT Insight
Why Eli Lilly Stock Sank 18% This Week

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$51.87 +0.82 (+1.61%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$51.88 +0.02 (+0.03%)
As of 08/8/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$625.15 -15.71 (-2.45%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$625.95 +0.80 (+0.13%)
As of 08/8/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.